Head-to-head comparison of all the prognostic models recommended by the European Association of Urology Guidelines to predict oncologic outcomes in patients with renal cell carcinoma

Local Treatment of Recurrent Renal Cell Carcinoma May Have a Significant Survival Effect Across All Risk-of-recurrence Groups

“…The Leibovich score is a scoring algorithm based on tumour stage, regional lymph node status, tumour size, nuclear grade and histologic tumour necrosis that can be used to predict disease progression after patients undergo RN for clinically localised ccRCC. For non-ccRCC, the UICC risk score was used [13] , [14] .…”

Predicting the Risk of Progression in Patients With Kidney Cancer: Aiming at the Optimal Tool in the Optimal Setting

“…In a recent head-to-head comparison and external validation of all the available prognostic models in renal cell carcinoma (RCC), Rosiello et al 3 systematically demonstrated that in clear-cell RCC, Leibovich 2018 resulted the most accurate model in predicting clinical progression (discrimination 0.88) and cancer-specific mortality (0.86), significantly outperforming the previous Leibovich 2003 score (which was developed including patients treated up to 52 years ago, incorporating variables which have been progressively modified over the years, eg, grade and tumor necrosis 4 ) and many other tools. Moreover, Venous tumor thrombus, Nuclear grade, Size, T and N Stage or University of California Los Angeles Integrated Staging System prognostic models predicting oncologic outcomes represented the most accurate in papillary (0.88 and 0.85) and chromophobe (0.88 and 0.89) RCC, respectively, 3 highlighting the necessity to use dedicated tools in histological settings different from clear cell. Moreover, although the recognized helpful aspects of a prospective trial, it is a well-known phenomenon that patients included in trials do not systematically represent the daily practice because of inclusion/exclusion criteria and many other confounding selection biases, limiting the generalizability of the results.…”

Identification of a claudin-low subtype in clear cell renal cell carcinoma with implications for the evaluation of clinical outcomes and treatment efficacy

“…Multiple prognostic models have been established and clinically verified to improve patient management, such as the UCLA Integrated Staging System (UISS), Leibovich score 2003/2018, VENUSS score, and GRANT score ( 4 ). However, these models are mainly based on traditional clinical and pathological variables and present with heterogeneous predictive accuracy according to the pathological characteristics ( 5 ). In the meantime, significant breakthroughs have been made in the past two decades, such as introducing vascular endothelial growth factor tyrosine kinase inhibitors (VEGFR TKIs), mammalian target of rapamycin (mTOR) inhibitors, and particularly immune checkpoint inhibitors (ICIs) to better manage patients with ccRCC.…”